Minerva Surgical price target lowered to $1 from $5 at Piper Sandler

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Minerva Surgical to $1 from $5 and keeps an Overweight rating on the shares following the Q1 sales beat. With the company having addressed its near-term financing issue, continued sales momentum "should help reinvigorate sentiment on the name," the analyst tells investors in a research note.